Skip to main content

Patient Support Line 1-800-282-7630, Monday – Friday: 9 AM – 5 PM ET

Get Personalized Support

We understand that starting a new treatment can feel overwhelming. That’s why the Novartis Patient Support team is here for you. Your free personalized program can help you and your caregivers throughout your KISQALI treatment journey. 

Sign up for Novartis Patient Support to receive: 

  • Information about your insurance coverage, including what your financial responsibility might be

  • A Patient Starter Kit to help you have a smooth start to treatment with KISQALI

  • Email communications tailored to your treatment journey

  • 1-on-1 support from a Patient Navigator who can guide you through various aspects of your treatment journey

You will receive a series of phone calls from a specially trained navigator.

The Patient Navigator Program is available for select Novartis Oncology products. Patient Navigator service does not involve the practice of nursing or provide clinical advice and counseling. 

To sign up for Novartis Patient Services program(s), please fill out the form below, and then click "Submit" when you're finished. You must be 18 years of age or older to participate in this program.

*Required fields.

Sign up for Novartis Patient Support

Select a State
Five digits only
By checking this box, I confirm that I am taking KISQALI for an approved use, consistent with the product's prescribing information. See below for approved uses. Please note not all approved indications qualify for the Patient Navigator program. 
I confirm I’d like to enroll in Novartis Patient Support and agree to receive recurring phone calls from a Novartis Patient Navigator at the number(s) provided. Calls may be prerecorded or autodialed. Consent and participation in Novartis Patient Support is not a condition of purchase of a product or service.
Gender *
OK to leave detailed voice mail about your medication on your phone *
Type of Insurance *
By clicking “Submit,” you represent that you are 18 years or older and agree to the Novartis Pharmaceuticals Corporation Terms of Use. You understand and agree that the information you provide will be used in accordance with the Novartis Privacy Policy, including to provide you with marketing and non-marketing calls and texts from Novartis and on its behalf about KISQALI and related products, surveys, support, and services, including calls/texts made with an autodialer or prerecorded voice, at the phone number above. You understand that unless you unsubscribe, by calling 1-800-282-7630 or clicking unsubscribe in a promotional e-mail, your consent will remain valid.


Thank you!

You are now registered to receive updates about KISQALI® (ribociclib). You will begin to receive communications shortly, with useful information including:

  • Treatment expectations
  • Financial assistance information
  • Encouragement to help you be your own best advocate
  • Metastatic breast cancer resources

Important Safety Information

What is the most important information I should know about KISQALI ?

KISQALI may cause serious side effects, including:

Lung problems. KISQALI may cause severe or life-threatening inflammation of the lungs during treatment that may lead to death. Tell your health care provider right away if you have any new or...


KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has gotten worse or has spread to other parts of the body (metastatic), in combination with:

  • an aromatase inhibitor as the first endocrine-based therapy; or...